Table 2.
Correlations of CXCL13 plasma levels with disease activity parameters at baseline and following 6 months of treatment
| Time | Disease marker | 0 months rho ( P ) | 6 months rho ( P ) |
|---|---|---|---|
| Baseline | |||
| IgM-RF | −0.112 (0.34) | 0.073 (0.54) | |
| Anti-CCP | 0.021 (0.86) | 0.099 (0.31) | |
| TSS | −0.011 (0.92) | 0.059 (0.62) | |
| Swollen joint count 28 | 0.336 (0.003) | 0.110 (0.35) | |
| Tender joint count 28 | 0.166 (0.16) | 0.001 (0.99) | |
| Swollen joint count 40 | 0.392 (0.001) | 0.177 (0.13) | |
| Tender joint count 40 | 0.162 (0.17) | 0.007 (0.95) | |
| VAS doctor global | 0.378 (0.001) | 0.103 (0.38) | |
| CRP | 0.094 (0.42) | 0.145 (0.21) | |
| DAS28CRP | 0.205 (0.078) | 0.089 (0.45) | |
| SDAI | 0.254 (0.028) | 0.091 (0.44) | |
| 12 months | |||
| Swollen joint count 28 | 0.131 (0.27) | −0.077 (0.51) | |
| Tender joint count 28 | 0.195 (0.096) | −0.012 (0.92) | |
| Swollen joint count 40 | 0.162 (0.17) | −0.085 (0.47) | |
| Tender joint count 40 | 0.219 (0.060) | 0.045 (0.71) | |
| VAS doctor | 0.006 (0.96) | −0.037 (0.76) | |
| CRP | −0.047 (0.69) | −0.124 (0.30) | |
| DAS28CRP | 0.059 (0.62) | 0.012 (0.92) | |
| SDAI | 0.009 (0.94) | 0.047 (0.67) |
Correlations of clinical data with the plasma level of CXCL13 measured at 0 months and after 6 months of treatment, in the OPERA trial. Correlations are presented as Spearman’s rho (P value). P values lower that 0.05 are considered statistically significant (indicated by bold). Statistically significant correlations between plasma CXCL13 level and disease parameters were observed at baseline, but not following treatment. Anti-CCP: anti-citrullinated protein antibody; CXCR13: C-X-C chemokine receptor type 13; CRP: C-reactive protein; DAS28CRP: disease activity in 28 joints, four variables, C-reactive protein based; IgM-RF: IgM rheumatic factor; OPERA: OPtimized treatment algorithm in Early Rheumatoid Arthritis; SDAI: simple disease activity index; TSS: total Sharp score; VAS: visual analog scale.